These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 25649659)

  • 1. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease.
    Olazarán J; Gil-de-Gómez L; Rodríguez-Martín A; Valentí-Soler M; Frades-Payo B; Marín-Muñoz J; Antúnez C; Frank-García A; Acedo-Jiménez C; Morlán-Gracia L; Petidier-Torregrossa R; Guisasola MC; Bermejo-Pareja F; Sánchez-Ferro Á; Pérez-Martínez DA; Manzano-Palomo S; Farquhar R; Rábano A; Calero M
    J Alzheimers Dis; 2015; 45(4):1157-73. PubMed ID: 25649659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment.
    Wang G; Zhou Y; Huang FJ; Tang HD; Xu XH; Liu JJ; Wang Y; Deng YL; Ren RJ; Xu W; Ma JF; Zhang YN; Zhao AH; Chen SD; Jia W
    J Proteome Res; 2014 May; 13(5):2649-58. PubMed ID: 24694177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered Expression Profile of Phosphatidylinositols in Erythrocytes of Alzheimer's Disease and Amnestic Mild Cognitive Impairment Patients.
    Chen Y; Lin C; Guo Z; Zhao S; Zhu Y; Huang F; Shui G; Lam SM; Pu J; Yan Y; Liu Z; Zhang B
    J Alzheimers Dis; 2020; 73(2):811-818. PubMed ID: 31868671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma amyloid-β oligomers and soluble tumor necrosis factor receptors as potential biomarkers of AD.
    Zhang J; Peng M; Jia J
    Curr Alzheimer Res; 2014 May; 11(4):325-31. PubMed ID: 24635842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort.
    Liu P; Wu L; Peng G; Han Y; Tang R; Ge J; Zhang L; Jia L; Yue S; Zhou K; Li L; Luo B; Wang B
    Brain Behav Immun; 2019 Aug; 80():633-643. PubMed ID: 31063846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Panel of Long Noncoding RNAs as Diagnostic Biomarkers for Amnestic Mild Cognitive Impairment in Peripheral Blood.
    Wang T; Zhang W; Maclin JMA; Xu H; Hong B; Yan F; Liu Y; He H; Liang H; Li C; Fang Y; Xiao S
    J Alzheimers Dis; 2024; 99(4):1385-1396. PubMed ID: 38788072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Blood Biomarkers that Correlate with Cognitive Performance and Hippocampal Volumetry: Potential for Early Diagnosis of Alzheimer's Disease.
    Hudd F; Shiel A; Harris M; Bowdler P; McCann B; Tsivos D; Wearn A; Knight M; Kauppinen R; Coulthard E; White P; Conway ME
    J Alzheimers Dis; 2019; 67(3):931-947. PubMed ID: 30689581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease.
    Wang T; Xiao S; Liu Y; Lin Z; Su N; Li X; Li G; Zhang M; Fang Y
    Int J Geriatr Psychiatry; 2014 Jul; 29(7):713-9. PubMed ID: 24318929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
    Johnstone D; Milward EA; Berretta R; Moscato P;
    PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.
    Oh J; Lee HJ; Song JH; Park SI; Kim H
    Exp Gerontol; 2014 Dec; 60():87-91. PubMed ID: 25304332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of plasma apolipoproteins and levels of inflammation-related factors with different stages of Alzheimer's disease: a cross-sectional study.
    Wang T; Wang X; Yao Y; Zhao C; Yang C; Han Y; Cai Y
    BMJ Open; 2022 Apr; 12(4):e054347. PubMed ID: 35387811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum metabolomic profiling in patients with Alzheimer disease and amnestic mild cognitive impairment by GC/MS.
    Sun C; Gao M; Wang F; Yun Y; Sun Q; Guo R; Yan C; Sun X; Li Y
    Biomed Chromatogr; 2020 Sep; 34(9):e4875. PubMed ID: 32384189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amnestic mild cognitive impairment and conversion to Alzheimer's disease: insulin resistance and glycoxidation as early biomarker clusters.
    Monacelli F; Borghi R; Cammarata S; Nencioni A; Piccini A; Tabaton M; Odetti P
    J Alzheimers Dis; 2015; 45(1):89-95. PubMed ID: 25471189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of mild cognitive impairment that evolves into Alzheimer's disease dementia within two years using a gene expression signature in blood: a pilot study.
    Roed L; Grave G; Lindahl T; Rian E; Horndalsveen PO; Lannfelt L; Nilsson C; Swenson F; Lönneborg A; Sharma P; Sjögren M
    J Alzheimers Dis; 2013; 35(3):611-21. PubMed ID: 23478308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte telomere length in mild cognitive impairment and Alzheimer's disease patients.
    Scarabino D; Broggio E; Gambina G; Corbo RM
    Exp Gerontol; 2017 Nov; 98():143-147. PubMed ID: 28827085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.
    Soares HD; Potter WZ; Pickering E; Kuhn M; Immermann FW; Shera DM; Ferm M; Dean RA; Simon AJ; Swenson F; Siuciak JA; Kaplow J; Thambisetty M; Zagouras P; Koroshetz WJ; Wan HI; Trojanowski JQ; Shaw LM;
    Arch Neurol; 2012 Oct; 69(10):1310-7. PubMed ID: 22801723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment.
    Wang T; Chen K; Li H; Dong S; Su N; Liu Y; Cheng Y; Dai J; Yang C; Xiao S
    J Clin Psychiatry; 2015 Feb; 76(2):135-41. PubMed ID: 25742200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer's Disease and Amnesic Mild Cognitive Impairment.
    Kobayashi N; Shinagawa S; Nagata T; Shimada K; Shibata N; Ohnuma T; Kasanuki K; Arai H; Yamada H; Nakayama K; Kondo K
    PLoS One; 2016; 11(1):e0146449. PubMed ID: 26742120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma fatty acid lipidomics in amnestic mild cognitive impairment and Alzheimer's disease.
    Iuliano L; Pacelli A; Ciacciarelli M; Zerbinati C; Fagioli S; Piras F; Orfei MD; Bossù P; Pazzelli F; Serviddio G; Caltagirone C; Spalletta G
    J Alzheimers Dis; 2013; 36(3):545-53. PubMed ID: 23635405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.